The abstract is read at the publisher; the summary is JClub's.
In postoperative high-risk locally advanced squamous cell carcinoma of the head and neck, weekly cisplatin achieved 5-year overall survival of 71.2% versus 58.7% with 3-weekly cisplatin.
- Why it matters: The trial addresses whether a less frequent cisplatin schedule can maintain survival outcomes in postoperative high-risk LA-SCCHN, where treatment burden and toxicity are key concerns.
- What they did: In JCOG1008, 261 patients were randomized to chemoradiotherapy with either 3-weekly cisplatin (100 mg/m² for three cycles) or weekly cisplatin (40 mg/m² for seven cycles), with final analysis at 5.6 years median follow-up.
- The result: At final analysis, weekly cisplatin confirmed noninferiority for overall survival (hazard ratio 0.76, 95% CI 0.52 to 1.12, <1.32), with no late adverse event differing by more than 10%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.